Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

Published 7y ago

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo Merck & Co’s cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announc... More »